CTMX
Price:
$1.2
Market Cap:
$93.74M
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical tri...[Read more]
Industry
Biotechnology
IPO Date
2015-10-08
Stock Exchange
NASDAQ
Ticker
CTMX
According to CytomX Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is 8.00. This represents a change of -17.40% compared to the average of 9.69 of the last 4 quarters.
The mean historical PE Ratio of CytomX Therapeutics, Inc. over the last ten years is -27.08. The current 8.00 PE Ratio has changed -3054.24% with respect to the historical average. Over the past ten years (40 quarters), CTMX's PE Ratio was at its highest in in the December 2017 quarter at 326.30. The PE Ratio was at its lowest in in the September 2014 quarter at -31.38.
Average
-27.08
Median
-7.10
Minimum
-201.06
Maximum
-1.08
Discovering the peaks and valleys of CytomX Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 18.50%
Maximum Annual PE Ratio = -1.08
Minimum Annual Increase = -68.61%
Minimum Annual PE Ratio = -201.06
Year | PE Ratio | Change |
---|---|---|
2023 | -201.06 | 18.50% |
2022 | -1.08 | -68.61% |
2021 | -3.44 | -62.53% |
2020 | -9.19 | 149.43% |
2019 | -3.68 | -50.45% |
2018 | -7.44 | -59.15% |
2017 | -18.20 | 169.26% |
2016 | -6.76 | 33.32% |
2015 | -5.07 | -65.88% |
2014 | -14.86 | -50.04% |
The current PE Ratio of CytomX Therapeutics, Inc. (CTMX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-68.53
5-year avg
-43.69
10-year avg
-27.08
CytomX Therapeutics, Inc.’s PE Ratio is greater than Spero Therapeutics, Inc. (4.06), greater than Neoleukin Therapeutics, Inc. (-0.98), greater than Instil Bio, Inc. (-0.78), greater than NextCure, Inc. (-0.65), greater than Assembly Biosciences, Inc. (-2.10), greater than Achilles Therapeutics plc (-0.45), greater than Nuvation Bio Inc. (-1.34),
Company | PE Ratio | Market cap |
---|---|---|
4.06 | $71.07M | |
-0.98 | $8.20M | |
-0.78 | $92.68M | |
-0.65 | $39.73M | |
-2.10 | $107.81M | |
-0.45 | $29.58M | |
-1.34 | $692.60M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like CytomX Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like CytomX Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is CytomX Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for CytomX Therapeutics, Inc. (CTMX)?
What is the highest PE Ratio for CytomX Therapeutics, Inc. (CTMX)?
What is the 3-year average PE Ratio for CytomX Therapeutics, Inc. (CTMX)?
What is the 5-year average PE Ratio for CytomX Therapeutics, Inc. (CTMX)?
How does the current PE Ratio for CytomX Therapeutics, Inc. (CTMX) compare to its historical average?